Context Therapeutics vs TuHURA Biosciences
CNTX and HURA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNTX and HURA compare
TuHURA Biosciences is the larger company, worth 5.7 times as much as Context Therapeutics ($89.2M against $15.7M).
Context Therapeutics scores higher on the StockData Score (6 against 0 for TuHURA Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNTX | HURA |
|---|---|---|
| Size and price | ||
| Market cap | $15.7M | $89.2M |
| Share price | $0.171 | $1.40 |
| Change, 1 year | −85.3% | −31.7% |
| Change, 5 years | −96.6% | −99.9% |
| Beta (5Y) | 0.09 | 1.98 |
| Employees | 15 | 22 |
| StockData Score | ||
| Total score | 6 (better) | 0 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.4× (better) | 4.8× |
| FCF yield | −217% | −33.5% (better) |
| Profitability | ||
| Return on equity | −76.1% (better) | −161% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 5.81 (better) | 0.18 |
| Altman Z-score | −5.99 | −3.21 (better) |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −0.10% (better) | −22.6% |
| Shareholder yield | −0.10% (better) | −22.6% |
| Ownership | ||
| Held by institutions | 68.4% | 14.1% |
| Held by insiders | 1.9% | 4.9% |
| Short interest, % of float | 5.2% | 10.2% |
Go deeper
- CNTX stock overview
- CNTX income statement
- CNTX valuation and score
- HURA stock overview
- HURA income statement
- HURA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.